Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levocetirizine
Drug ID BADD_D01272
Description Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine].[L7694] Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Indications and Usage Levocetirizine is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older.
Marketing Status Prescription; OTC; Discontinued
ATC Code R06AE09
DrugBank ID DB06282
KEGG ID D07402
MeSH ID C472067
PubChem ID 1549000
TTD Drug ID D0M8PW
NDC Product Code Not Available
Synonyms levocetirizine | levocetrizine | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- | (2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid | levocetirizine hydrochloride | Xusal | levocetirizine dihydrochloride | (2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride | cetirizine (R)-form dihydrochloride | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride | Xyzal | UCB-28556
Chemical Information
Molecular Formula C21H25ClN2O3
CAS Registry Number 130018-77-8
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyskinesia17.01.02.006--
Dysphagia07.01.06.0030.000877%
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.0040.001169%
Dyspnoea22.02.01.004; 02.01.03.0020.003508%
Dysuria20.02.02.002--
Electrocardiogram QT prolonged13.14.05.0040.002046%
Epilepsy17.12.03.0020.001169%Not Available
Epistaxis24.07.01.005; 22.04.03.0010.000585%
Erythema23.03.06.0010.001754%Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.002631%
Extrapyramidal disorder17.01.02.0070.000585%
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.001169%
Faeces hard07.01.03.0030.000585%Not Available
Fatigue08.01.01.002--
Febrile convulsion17.12.03.004; 08.05.02.0090.003508%Not Available
Feeling abnormal08.01.09.014--Not Available
Fixed drug eruption23.03.05.006; 10.01.01.022; 08.01.06.017--Not Available
Gamma-glutamyltransferase increased13.03.01.0110.000877%
Glomerulonephritis20.05.01.001; 10.02.01.006--Not Available
Haemorrhage subcutaneous24.07.06.010; 23.06.07.0020.001462%Not Available
Haemorrhoids24.10.02.002; 07.15.03.0010.000585%
Hallucination19.10.02.0020.001462%
Headache17.14.01.0010.002631%
Hepatic atrophy09.01.08.0040.000585%Not Available
Hepatic encephalopathy17.13.01.003; 09.01.03.0060.000585%Not Available
Hepatic failure09.01.03.0020.000153%
Hepatic function abnormal09.01.02.0010.002631%Not Available
Hepatitis09.01.07.004--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages